Tesamorelin 10 mg — Research Consultation
Tesamorelin is a synthetic GHRH(1-44) analogue stabilised by an N-terminal hexenoyl group, conferring resistance to dipeptidyl peptidase IV. Published research describes pulsatile growth-hormone-release pharmacology and IGF-1 endpoints in long-term administration studies.
What Tesamorelin is
Tesamorelin is the trans-3-hexenoyl modification of GHRH(1-44), a 44-amino-acid stabilised analogue of endogenous growth-hormone-releasing hormone. The N-terminal modification protects against dipeptidyl peptidase IV degradation, giving Tesamorelin a longer plasma half-life than native GHRH while preserving GHRH-receptor agonism.
What the published literature covers
Published pharmacology research describes Tesamorelin pulsatile-GH release patterns, IGF-1 dose-response curves over multi-week administration, and the absence of meaningful glucose-tolerance disruption at active research doses. The receptor-mechanism research base is well-developed; long-term safety endpoints have been studied in extended-duration clinical research.
Quality verification
Lyophilised Tesamorelin manufactured under ICH Q7 GMP standards. Independent HPLC verification at a US-based third-party laboratory, ≥98% peak-area purity. COA available through the in-chat consultation.
Common research questions
- Is Tesamorelin legal in the UAE?
- Tesamorelin is classified as a research compound in the UAE and is sold through standard wellness-supply channels with VAT compliance applied to every dispatch.
- What dose ranges does the published research describe?
- Published pharmacology research uses 1-2 mg subcutaneous daily administration. Grey-research protocols mirror this range, often cycling 8-12 weeks on / 4-8 weeks off. IGF-1 endpoints rise within the first 2-4 weeks of administration.
- Tesamorelin vs. CJC-1295?
- Both are stabilised GHRH analogues but use different stabilisation strategies. CJC-1295 (no-DAC) substitutes four amino acids; the DAC variant adds an albumin-binding tag. Tesamorelin modifies the N-terminus with a hexenoyl group. The half-lives, receptor-binding kinetics, and reconstitution chemistry differ.
- Why pair with a GHRP?
- GHRH analogues and GHRPs activate different receptors and produce additive GH release in the published combined-signalling research model. Researchers studying the additive paradigm sometimes pair Tesamorelin with Ipamorelin or another GHRP.
- How is purity verified?
- HPLC peak-area purity (≥98%) at a US-based third-party laboratory. COA available through the chat.
- Shelf life and storage?
- Lyophilised powder is ambient-temperature stable in transit; -20°C long-term storage; refrigerated post-reconstitution per the supplied protocol.
- How fast is delivery in the UAE?
- Same-day delivery within Dubai, next-business-day across the rest of the UAE.
Peer-reviewed references
Related consultations
Further reading
Talk to Nour about your research protocol
Nour reads the peer-reviewed literature and walks you through what each compound is best suited for. English or Arabic, inside the chat.